A comparison of haploidentical versus HLA-identical sibling outpatient hematopoietic cell transplantation using reduced intensity conditioning in patients with acute leukemia.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 13 03 2024
accepted: 12 09 2024
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

Hematopoietic cell transplantation (HCT) increases survival for acute leukemia. Outpatient allogeneic HCT reduces costs and increases transplant rates in developing countries. We report outcomes of outpatient HLA-identical and haploidentical HCT in acute leukemia. This single-center retrospective cohort study analyzed 121 adult patients with acute myeloblastic (AML) and acute lymphoblastic leukemia (ALL) receiving an outpatient allogeneic HCT with peripheral blood allografts after reduced-intensity conditioning (RIC) from 2012-2022. There were 81 (67%) haploidentical and 40 (33%) HLA-identical transplants. Complete chimerism (CC) at day +100 was not different in HLA-identical compared to haploidentical HCT (32.5% and 38.2%, Outpatient peripheral blood allogenic HCT after RIC is a valid and effective alternative for adult patients suffering acute myeloblastic or lymphoblastic leukemia in low-income populations.

Sections du résumé

Background UNASSIGNED
Hematopoietic cell transplantation (HCT) increases survival for acute leukemia. Outpatient allogeneic HCT reduces costs and increases transplant rates in developing countries. We report outcomes of outpatient HLA-identical and haploidentical HCT in acute leukemia.
Methods UNASSIGNED
This single-center retrospective cohort study analyzed 121 adult patients with acute myeloblastic (AML) and acute lymphoblastic leukemia (ALL) receiving an outpatient allogeneic HCT with peripheral blood allografts after reduced-intensity conditioning (RIC) from 2012-2022.
Results UNASSIGNED
There were 81 (67%) haploidentical and 40 (33%) HLA-identical transplants. Complete chimerism (CC) at day +100 was not different in HLA-identical compared to haploidentical HCT (32.5% and 38.2%,
Conclusions UNASSIGNED
Outpatient peripheral blood allogenic HCT after RIC is a valid and effective alternative for adult patients suffering acute myeloblastic or lymphoblastic leukemia in low-income populations.

Identifiants

pubmed: 39430740
doi: 10.3389/fimmu.2024.1400610
pmc: PMC11486716
doi:

Substances chimiques

HLA Antigens 0

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1400610

Informations de copyright

Copyright © 2024 Jaime-Pérez, Valdespino-Valdes, Gómez-De León, Barragán-Longoria, Dominguez-Villanueva, Cantú-Rodríguez, Gutiérrez-Aguirre and Gómez-Almaguer.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

José Carlos Jaime-Pérez (JC)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Jorge Valdespino-Valdes (J)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Andrés Gómez-De León (A)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Renata Valeria Barragán-Longoria (RV)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Adriana Dominguez-Villanueva (A)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Olga Graciela Cantú-Rodríguez (OG)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

César Homero Gutiérrez-Aguirre (CH)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

David Gómez-Almaguer (D)

Hematology Department, Internal Medicine Division, Dr. José E. González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH